期刊文献+

雷替曲塞联合奥沙利铂治疗晚期肠癌的效果观察 被引量:1

Effectiveness discussion of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer
下载PDF
导出
摘要 目的:探讨雷替曲塞联合奥沙利铂治疗晚期肠癌的临床效果。方法选择2012年5月∽2013年8月在本院进行治疗的晚期肠癌患者36例,将其随机分为观察组和对照组各18例,对照组采用奥沙利铂联合氟尿嘧啶与亚叶酸钙进行治疗,观察组采用雷替曲塞联合奥沙利铂进行治疗,比较两组的临床治疗效果。结果观察组总有效率为38.9%,对照组总有效率为16.7%,两组差异有统计学意义(P〈0.05);观察组不良反应发生率为5.6%,对照组不良反应发生率为27.8%,两组差异有统计学意义(P〈0.05)。结论雷替曲塞联合奥沙利铂治疗晚期肠癌可取得较好的临床效果,能够有效缓解临床症状,显著改善肠道功能,有效提高患者的生活质量及生命质量,是一种比较理想的治疗方法,值得临床广泛应用。 Objective To discuss the clinical effectiveness of raltitrexed combined with oxaliplatin in the treatment of advanced colorectal cancer. Methods 36 cases of patients with advanced colorectal cancer admitted into our hospital from May 2012 to August 2013 were selected and evenly divided into observation group and control group in random. Patients in control group were treated by the combination of oxaliplatin,fluorouracil and leucovorin.Patients in observa-tion group were provided with raltitrexed and oxaliplatin.Clinical effect between the two groups were compared. Results The total clinical effective rate was 38.9% in treatment group and 16.7% in control group,the difference between two groups was significant (P〈0.05).The incidence of adverse reactions was 5.6% in treatment group and 27.8% in control group,with significant difference (P〈0.05). Conclusion For patients with advanced colorectal cancer,raltitrexed com-bined with oxaliplatin can achieve a better clinical effect,can relieve the patent’s clinical symptoms,significantly im-prove patient’s intestinal function,so as to effectively improve patient’s quality of life,is an ideal treatment for advanced colorectal cancer,and is worthy of widely using in clinical practice.
作者 杭兆康
出处 《中国当代医药》 2014年第22期75-76,共2页 China Modern Medicine
关键词 晚期肠癌 雷替曲塞 奥沙利铂 Advanced colorectal cancer Raltitrexed Oxaliplatin
  • 相关文献

参考文献10

二级参考文献79

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1571
  • 2束永前,刘凌翔,刘平,黄普文,殷咏梅,卢凯华,刘连科.5-Fu/LV+L-OHP方案静脉及腹腔热灌注化疗对T_4期结直肠癌的疗效对比观察[J].实用癌症杂志,2005,20(3):282-285. 被引量:8
  • 3Andre T, Louvet C, Maindrault-Coebel F,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFI- RI) for pretreated metastatic colorectal cancer [ J ]. Eur J Cancer, 1999,35 (9) : 1343 - 7.
  • 4Maindrauh-Goebel F, de Gramont A,Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer[ J ].Ann Onco1,2000,11 ( 11 ) : 1477 - 1483.
  • 5Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic eoloreetal cancer: the NO16966 trial [ J]. Clin Coloreetal Cancer,2006,6(4) :261 - 264.
  • 6Jackman AL, Farrugia DC, Gibsonw, et al. ZD1694 (tomudex) : a new thymidylate synthase inhibitor with activity in colorectal cancer [ J]. Eur J Cancer, 1995,31A ( 7/8 ) : 1277 - 1282.
  • 7Aschele C, Baldo C, Sobrero AF, et al. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells [ J ]. Clin Cancer Res, 1998,4 ( 5 ) :1323 - 1330.
  • 8Laudani A, Gebbia V, Leonardi V, et al. Activity and toxicity of oxaliplatin plus raltit rexed in 5-fluorouracil ref ractory meta-static colorectal adeno2carcinoma [ J ]. Anticancer Res,2004,24(2) :1139 - 1142.
  • 9Cortinovis D, Bajetta E, Di Bartolomeo M, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer [ J ]. Tumori ,2004,90 ( 2 ) : 186 - 191.
  • 10Martoni A, Mini E, Pinto C, et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study [ J]. Anticancer Res,2003,23 (1B): 687 -691.

共引文献212

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部